Boston Scientific said net sales for Q4 2024 were $4.561 billion, growing 22.4% on a reported basis, 23.1% on an operational basis and 19.5% on an organic basis, all compared to the prior year period.

1. 01

   Boston Scientific said net sales for Q4 2024 were $4.561 billion, growing 22.4% on a reported basis, 23.1% on an operational basis and 19.5% on an organic basis, all compared to the prior year period.

2. 02

   The company reported net sales of $16.747 billion for 2024, growing 17.6% on a reported basis, GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, and adjusted EPS of $2.51.

3. 03

   Boston Scientific said Cardiovascular net sales for Q4 2024 grew 28.8% on a reported basis and MedSurg grew 12.4%, compared to the prior year period, while United States regional sales grew 30.7%.

4. 04

   The company estimated net sales growth for 2025 versus the prior year period to be in a range of approximately 12.5 to 14.5% on a reported basis and approximately 10 to 12% on an organic basis, GAAP EPS in a range of $1.86 to $1.93, and adjusted EPS of $2.80 to $2.87.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.